CereVasc raises $70M in Series B funding for eShunt System development in Normal Pressure Hydrocephalus.
CereVasc raises $70M Series B, led by Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund. Proceeds to support the clinical development of its novel eShunt System for Normal Pressure Hydrocephalus, including the STRIDE pivotal trial. The eShunt System offers a minimally invasive treatment with potential benefits over current standard of care, ventriculo-peritonal shunt.
May 13, 2024
3 Articles